$CLOV
CLOVER HEALTH INVESTMENTS, CORP. /DE Stock $clov

$clov Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-Q Financial Statement

#000180117023000038 Filed on May 09, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022 Q1
Revenue	$527.8M	$898.8M	$874.4M
YoY Change	-39.64%	108.04%	336.48%
Cost Of Revenue	$472.5M		$861.7M
YoY Change	-45.17%		301.89%
Gross Profit	$55.29M		$12.66M
YoY Change	336.79%		-189.8%
Gross Profit Margin	10.48%		1.45%
Selling, General & Admin	$129.4M	$124.3M	$126.8M
YoY Change	2.08%	8.88%	21.21%
% of Gross Profit	234.1%		1001.72%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$279.0K	-$841.0K	$826.0K
YoY Change	-66.22%	-199.17%	416.25%
% of Gross Profit	0.5%		6.53%
Operating Expenses	$600.4M	$1.006B	$961.7M
YoY Change	-37.57%	62.56%	201.08%
Operating Profit	-$72.61M		-$87.30M
YoY Change	-16.83%		-26.69%
Interest Expense	$0.00	-$206.0K	$403.0K
YoY Change	-100.0%	-50.0%	-65.7%
% of Operating Profit
Other Income/Expense, Net		-$3.000K	$0.00
YoY Change			-100.0%
Pretax Income	-$72.61M	-$84.05M	-$75.31M
YoY Change	-3.59%	-55.1%	55.6%
Income Tax
% Of Pretax Income
Net Earnings	-$72.61M	-$84.05M	-$75.31M
YoY Change	-3.59%	-55.1%	55.54%
Net Earnings / Revenue	-13.76%	-9.35%	-8.61%
Basic Earnings Per Share	-$0.15		-$0.16
Diluted Earnings Per Share	-$0.15	-$0.18	-$0.16
COMMON SHARES
Basic Shares Outstanding	478.8M shares		473.0M shares
Diluted Shares Outstanding	478.8M shares		473.0M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$347.1M	$293.3M	$351.2M
YoY Change	-1.18%	-8.66%	-13.38%
Cash & Equivalents	$190.6M	$103.8M	$273.8M
Short-Term Investments	$156.5M	$189.5M	$77.40M
Other Short-Term Assets	$2.771M	$4.043M	$17.18M
YoY Change	-83.87%	-77.57%	-19.19%
Inventory
Prepaid Expenses	$16.90M	$18.15M	$21.94M
Receivables
Other Receivables
Total Short-Term Assets	$1.274B	$625.0M	$2.491B
YoY Change	-48.85%	-16.95%	207.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.547M	$5.753M	$2.311M
YoY Change	96.75%	151.55%	14.18%
Goodwill		$11.75M
YoY Change		879.08%
Intangibles
YoY Change
Long-Term Investments	$135.9M	$138.1M	$3.177M
YoY Change	4176.77%		-91.05%
Other Assets	$14.80M	$15.74M	$14.71M
YoY Change	0.64%	50.83%	70.2%
Total Long-Term Assets	$179.3M	$183.6M	$188.5M
YoY Change	-4.85%	-7.38%	227.83%
TOTAL ASSETS
Total Short-Term Assets	$1.274B	$625.0M	$2.491B
Total Long-Term Assets	$179.3M	$183.6M	$188.5M
Total Assets	$1.454B	$808.6M	$2.680B
YoY Change	-45.76%	-14.95%	209.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$47.45M	$32.45M	$27.45M
YoY Change	72.86%	15.34%	50.01%
Accrued Expenses	$32.17M	$25.79M	$14.00M
YoY Change	129.76%	41.65%	-10.82%
Deferred Revenue	$107.6M	$0.00
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.110B	$440.7M	$2.152B
YoY Change	-48.4%	18.26%	1143.76%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$19.95M
YoY Change	-100.0%	-100.0%	-17.86%
Other Long-Term Liabilities	$16.20M	$16.19M	$13.16M
YoY Change	23.06%	14.88%	-83.69%
Total Long-Term Liabilities	$16.20M	$16.19M	$33.11M
YoY Change	-51.07%	-52.42%	36.34%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.110B	$440.7M	$2.152B
Total Long-Term Liabilities	$16.20M	$16.19M	$33.11M
Total Liabilities	$1.130B	$460.9M	$2.190B
YoY Change	-48.38%	12.0%	687.78%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.019B	-$1.956B	-$1.692B
YoY Change	19.33%	20.96%	57.05%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)			$6.086M
YoY Change
Treasury Stock Shares			1.894M shares
Shareholders Equity	$323.1M	$347.7M	$489.8M
YoY Change
Total Liabilities & Shareholders Equity	$1.454B	$808.6M	$2.680B
YoY Change	-45.76%	-14.95%	209.12%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022 Q1
OPERATING ACTIVITIES
Net Income	-$72.61M	-$84.05M	-$75.31M
YoY Change	-3.59%	-55.1%	55.54%
Depreciation, Depletion And Amortization	$279.0K	-$841.0K	$826.0K
YoY Change	-66.22%	-199.17%	416.25%
Cash From Operating Activities	$79.03M	-$209.4M	-$57.04M
YoY Change	-238.55%	161.14%	-38.58%
INVESTING ACTIVITIES
Capital Expenditures	$251.0K	$3.877M	$158.0K
YoY Change	58.86%	-1728.99%	59.6%
Acquisitions
YoY Change
Other Investing Activities	$10.43M	$16.53M	$36.67M
YoY Change	-71.55%	-115.56%	-114.25%
Cash From Investing Activities	$10.18M	$12.66M	$36.51M
YoY Change	-72.12%	-111.88%	-114.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$2.982M		$5.939M
YoY Change	-49.79%		-563.26%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$2.134M	56.00K	-$5.608M
YoY Change	-61.95%	-99.98%	-100.85%
NET CHANGE
Cash From Operating Activities	$79.03M	-209.4M	-$57.04M
Cash From Investing Activities	$10.18M	12.66M	$36.51M
Cash From Financing Activities	-$2.134M	56.00K	-$5.608M
Net Change In Cash	$87.08M	-196.7M	-$26.14M
YoY Change	-433.16%	-301.28%	-108.37%
FREE CASH FLOW
Cash From Operating Activities	$79.03M	-$209.4M	-$57.04M
Capital Expenditures	$251.0K	$3.877M	$158.0K
Free Cash Flow	$78.78M	-$213.2M	-$57.20M
YoY Change	-237.73%	166.76%	-38.47%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001801170
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	CLOVER HEALTH INVESTMENTS, CORP. /DE
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-39252
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1515192
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	3401 Mallory Lane
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 210
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Franklin
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	TN
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	37067
CY2023Q1	dei	City Area Code CityAreaCode	201
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	432-2133
CY2023Q1	dei	Security12g Title Security12gTitle	Class A Common Stock, par value $0.0001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	CLOV
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	190562000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	103791000	usd
CY2023Q1	us-gaap	Other Short Term Investments OtherShortTermInvestments	69478000	usd
CY2022Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	41457000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	159062000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	193300000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	156542000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	189498000	usd
CY2023Q1	us-gaap	Debt Securities Held To Maturity Fair Value Current DebtSecuritiesHeldToMaturityFairValueCurrent	15000	usd
CY2022Q4	us-gaap	Debt Securities Held To Maturity Fair Value Current DebtSecuritiesHeldToMaturityFairValueCurrent	15000	usd
CY2023Q1	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	15000	usd
CY2022Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	15000	usd
CY2023Q1	clov	Accrued Retrospective Premiums Current AccruedRetrospectivePremiumsCurrent	70185000	usd
CY2022Q4	clov	Accrued Retrospective Premiums Current AccruedRetrospectivePremiumsCurrent	20387000	usd
CY2023Q1	us-gaap	Other Receivables OtherReceivables	24291000	usd
CY2022Q4	us-gaap	Other Receivables OtherReceivables	23596000	usd
CY2023Q1	us-gaap	Receivables From Customers ReceivablesFromCustomers	56943000	usd
CY2022Q4	us-gaap	Receivables From Customers ReceivablesFromCustomers	70607000	usd
CY2023Q1	clov	Non Insurance Performance Year Receivable Current NonInsurancePerformanceYearReceivableCurrent	552620000	usd
CY2022Q4	clov	Non Insurance Performance Year Receivable Current NonInsurancePerformanceYearReceivableCurrent	0	usd
CY2023Q1	clov	Non Insurance Receivable NonInsuranceReceivable	53625000	usd
CY2022Q4	clov	Non Insurance Receivable NonInsuranceReceivable	52955000	usd
CY2023Q1	us-gaap	Deposits Assets Current DepositsAssetsCurrent	80329000	usd
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	100502000	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	16898000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	18146000	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	2771000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	4043000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	1274259000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	624997000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	139643000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	142940000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	135132000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	137368000	usd
CY2023Q1	us-gaap	Debt Securities Held To Maturity Fair Value Noncurrent DebtSecuritiesHeldToMaturityFairValueNoncurrent	651000	usd
CY2022Q4	us-gaap	Debt Securities Held To Maturity Fair Value Noncurrent DebtSecuritiesHeldToMaturityFairValueNoncurrent	636000	usd
CY2023Q1	us-gaap	Held To Maturity Securities Noncurrent HeldToMaturitySecuritiesNoncurrent	741000	usd
CY2022Q4	us-gaap	Held To Maturity Securities Noncurrent HeldToMaturitySecuritiesNoncurrent	742000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4547000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5753000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4109000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4025000	usd
CY2023Q1	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	20000000	usd
CY2022Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	20000000	usd
CY2022Q4	us-gaap	Receivables From Customers ReceivablesFromCustomers	70600000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	14801000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	15735000	usd
CY2023Q1	us-gaap	Assets Assets	1453589000	usd
CY2022Q4	us-gaap	Assets Assets	808620000	usd
CY2023Q1	us-gaap	Assumed Liability For Unpaid Claims And Claims Adjustment Expense AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	141258000	usd
CY2022Q4	us-gaap	Assumed Liability For Unpaid Claims And Claims Adjustment Expense AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	141947000	usd
CY2023Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	1331000	usd
CY2022Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	1566000	usd
CY2023Q1	clov	Non Insurance Performance Year Obligation Current NonInsurancePerformanceYearObligationCurrent	613057000	usd
CY2022Q4	clov	Non Insurance Performance Year Obligation Current NonInsurancePerformanceYearObligationCurrent	73844000	usd
CY2023Q1	clov	Non Insurance Payable Current NonInsurancePayableCurrent	160942000	usd
CY2022Q4	clov	Non Insurance Payable Current NonInsurancePayableCurrent	148191000	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	47452000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	32445000	usd
CY2023Q1	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	30306000	usd
CY2022Q4	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	23962000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	107563000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1862000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1827000	usd
CY2023Q1	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	5430000	usd
CY2022Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	7239000	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1173000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	486000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1110374000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	431507000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3908000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4033000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	16200000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	16193000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	1130482000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	451733000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2358622000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2319157000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-7031000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-9374000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2019039000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1946433000	usd
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	5006473	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	2072752	shares
CY2023Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	9491000	usd
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	6509000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	323107000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	356887000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1453589000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	808620000	usd
CY2023Q1	us-gaap	Ceded Premiums Earned CededPremiumsEarned	122000	usd
CY2022Q1	us-gaap	Ceded Premiums Earned CededPremiumsEarned	119000	usd
CY2023Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	317086000	usd
CY2022Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	278169000	usd
CY2023Q1	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	205783000	usd
CY2022Q1	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	594898000	usd
CY2023Q1	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	4906000	usd
CY2022Q1	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	1312000	usd
CY2023Q1	us-gaap	Revenues Revenues	527775000	usd
CY2022Q1	us-gaap	Revenues Revenues	874379000	usd
CY2023Q1	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	472490000	usd
CY2022Q1	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	861722000	usd
CY2023Q1	us-gaap	Labor And Related Expense LaborAndRelatedExpense	70207000	usd
CY2022Q1	us-gaap	Labor And Related Expense LaborAndRelatedExpense	69091000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	59215000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	57697000	usd
CY2023Q1	clov	Premium Deficiency Testing Benefit Long Duration Contract Amount PremiumDeficiencyTestingBenefitLongDurationContractAmount	-1810000	usd
CY2022Q1	clov	Premium Deficiency Testing Benefit Long Duration Contract Amount PremiumDeficiencyTestingBenefitLongDurationContractAmount	-27476000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	279000	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	826000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	600381000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	961860000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-72606000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-87481000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	0	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	403000	usd
CY2023Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	usd
CY2022Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	12394000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-72606000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-75490000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	478805067	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	478805067	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	473028651	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	473028651	shares
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	2343000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-5324000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-70263000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-80814000	usd
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	540040000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	331000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	40640000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-5324000	usd
CY2022Q1	clov	Conversion From Class B To Class A Common Stock Amount ConversionFromClassBToClassACommonStockAmount	0	usd
CY2022Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	5939000	usd
CY2022Q1	us-gaap	Noncontrolling Interest Decrease From Deconsolidation NoncontrollingInterestDecreaseFromDeconsolidation	3903000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-75490000	usd
CY2022Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	490355000	usd
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	356887000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	848000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	38617000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	2343000	usd
CY2023Q1	clov	Conversion From Class B To Class A Common Stock Amount ConversionFromClassBToClassACommonStockAmount	0	usd
CY2023Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	2982000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-72606000	usd
CY2023Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2023Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	323107000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-72606000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-75490000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	279000	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	826000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	38617000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	40640000	usd
CY2023Q1	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	-923000	usd
CY2022Q1	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	-17000	usd
CY2023Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	usd
CY2022Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	12394000	usd
CY2023Q1	clov	Premium Deficiency Testing Benefit Long Duration Contract Amount PremiumDeficiencyTestingBenefitLongDurationContractAmount	-1810000	usd
CY2022Q1	clov	Premium Deficiency Testing Benefit Long Duration Contract Amount PremiumDeficiencyTestingBenefitLongDurationContractAmount	-27476000	usd
CY2023Q1	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	-49798000	usd
CY2022Q1	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	-22758000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	695000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-551000	usd
CY2023Q1	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-20481000	usd
CY2022Q1	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	2156000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1248000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	11934000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-3391000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-876000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-13664000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5863000	usd
CY2023Q1	clov	Increase Decrease In Non Insurance Receivable IncreaseDecreaseInNonInsuranceReceivable	670000	usd
CY2022Q1	clov	Increase Decrease In Non Insurance Receivable IncreaseDecreaseInNonInsuranceReceivable	38000	usd
CY2023Q1	clov	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-84000	usd
CY2022Q1	clov	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	1015000	usd
CY2023Q1	clov	Increase Decrease In Unpaid Claims IncreaseDecreaseInUnpaidClaims	-924000	usd
CY2022Q1	clov	Increase Decrease In Unpaid Claims IncreaseDecreaseInUnpaidClaims	25266000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	15007000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-678000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	6344000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-3557000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	107563000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	694000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-894000	usd
CY2023Q1	clov	Increase Decrease In Performance Year Obligation IncreaseDecreaseInPerformanceYearObligation	-13407000	usd
CY2022Q1	clov	Increase Decrease In Performance Year Obligation IncreaseDecreaseInPerformanceYearObligation	-16738000	usd
CY2023Q1	clov	Increase Decrease In Non Insurance Payable IncreaseDecreaseInNonInsurancePayable	12751000	usd
CY2022Q1	clov	Increase Decrease In Non Insurance Payable IncreaseDecreaseInNonInsurancePayable	43230000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-90000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1179000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	79032000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-57042000	usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	67893000	usd
CY2022Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	113079000	usd
CY2023Q1	clov	Proceeds From Sale Of Short Term Investments And Available For Sale Securities ProceedsFromSaleOfShortTermInvestmentsAndAvailableForSaleSecurities	15001000	usd
CY2022Q1	clov	Proceeds From Sale Of Short Term Investments And Available For Sale Securities ProceedsFromSaleOfShortTermInvestmentsAndAvailableForSaleSecurities	0	usd
CY2023Q1	clov	Proceeds From Maturity Of Short Term Investments And Debt Securities Available For Sale And Held To Maturity ProceedsFromMaturityOfShortTermInvestmentsAndDebtSecuritiesAvailableForSaleAndHeldToMaturity	63324000	usd
CY2022Q1	clov	Proceeds From Maturity Of Short Term Investments And Debt Securities Available For Sale And Held To Maturity ProceedsFromMaturityOfShortTermInvestmentsAndDebtSecuritiesAvailableForSaleAndHeldToMaturity	150000000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	251000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	158000	usd
CY2023Q1	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	0	usd
CY2022Q1	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	250000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	10181000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	36513000	usd
CY2023Q1	clov	Proceeds From Issuance Of Common Stock Net Of Early Exercise Liability ProceedsFromIssuanceOfCommonStockNetOfEarlyExerciseLiability	848000	usd
CY2022Q1	clov	Proceeds From Issuance Of Common Stock Net Of Early Exercise Liability ProceedsFromIssuanceOfCommonStockNetOfEarlyExerciseLiability	331000	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2982000	usd
CY2022Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	5939000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2134000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-5608000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	87079000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-26137000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	186213000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	299968000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	273292000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	273831000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	190562000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	273831000	usd
CY2023Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	82730000	usd
CY2022Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	273292000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	273831000	usd
CY2023Q1	clov	Performance Year Receivable PerformanceYearReceivable	552620000	usd
CY2022Q1	clov	Performance Year Receivable PerformanceYearReceivable	1743406000	usd
CY2023Q1	clov	Performance Year Obligation Non Cash Activities PerformanceYearObligationNonCashActivities	552620000	usd
CY2022Q1	clov	Performance Year Obligation Non Cash Activities PerformanceYearObligationNonCashActivities	1743406000	usd
CY2023Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	usd
CY2022Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	648000	usd
CY2023Q1	us-gaap	Transfer To Investments TransferToInvestments	0	usd
CY2022Q1	us-gaap	Transfer To Investments TransferToInvestments	8644000	usd
CY2023Q1	us-gaap	Noncontrolling Interest Decrease From Deconsolidation NoncontrollingInterestDecreaseFromDeconsolidation	0	usd
CY2022Q1	us-gaap	Noncontrolling Interest Decrease From Deconsolidation NoncontrollingInterestDecreaseFromDeconsolidation	3903000	usd
CY2023Q1	clov	Conversion Of Convertible Note To Preferred Stock ConversionOfConvertibleNoteToPreferredStock	0	usd
CY2022Q1	clov	Conversion Of Convertible Note To Preferred Stock ConversionOfConvertibleNoteToPreferredStock	250000	usd
CY2023Q1	clov	Direct Contracting Shared Savings And Losses Percent DirectContractingSharedSavingsAndLossesPercent	1.000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-75490000	usd
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and the accompanying notes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The area involving the most significant use of estimates is the amount of incurred but not reported claims. Many factors can cause actual outcomes to deviate from these assumptions and estimates, such as changes in economic conditions, changes in government healthcare policy, advances in medical technology, changes in treatment patterns, and changes in average lifespan. Accordingly, the Company cannot determine with precision the ultimate amounts that it will pay for, or the timing of payment of actual claims, or whether the assets supporting the liabilities will grow to the level the Company assumes prior to payment of claims. If the Company's </span></div>actual experience is different from its assumptions or estimates, the Company's reserves may prove inadequate. As a result, the Company would incur a charge to operations in the period in which it determines such a shortfall exists, which could have a material adverse effect on the Company's business, results of operations, and financial condition. Other areas involving significant estimates include risk adjustment provisions related to Medicare contracts and the valuation of the Company's investment securities, goodwill and other intangible assets, reinsurance, premium deficiency reserve, warrants, embedded derivative related to convertible securities, stock-based compensation, recoveries from third parties for coordination of benefits, ACO REACH Benchmark, specifically cost trend and risk score estimates that can develop over time, and final determination of medical cost adjustment pools.
CY2023Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts in the prior years' Consolidated Balance Sheets and Consolidated Statements of Cash Flows have been reclassified to conform to the current year's presentation, primarily related to Non-Insurance receivable, Other assets, current, and Performance year obligation. In addition amounts in the prior years' Consolidated Statements of Cash Flows have been reclassified to confirm with the current year's presentation related to cash used by Performance year obligation.</span></div>
CY2022Q1	clov	Decrease In Accumulated Deficit DecreaseInAccumulatedDeficit	700000	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1616000000	usd
CY2022Q1	clov	Premium Deficiency Testing Benefit Long Duration Contract Amount PremiumDeficiencyTestingBenefitLongDurationContractAmount	-27476000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	961860000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-87481000	usd
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2022Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	7239000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	431507000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	451733000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1946433000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	356887000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	808620000	usd
CY2021Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	109905000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	371901000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	410764000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1616015000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	540040000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	950804000	usd
CY2023Q1	clov	Premium Deficiency Testing Benefit Long Duration Contract Amount PremiumDeficiencyTestingBenefitLongDurationContractAmount	-1810000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	600381000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-72606000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-72606000	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2023Q1	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	5430000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1110374000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	1130482000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2019039000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	323107000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1453589000	usd
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2023Q1	clov	Deferred Policy Acquisition Costs Amortization Expense Premium Deficiency Reserve DeferredPolicyAcquisitionCostsAmortizationExpensePremiumDeficiencyReserve	0	usd
CY2022	clov	Deferred Policy Acquisition Costs Amortization Expense Premium Deficiency Reserve DeferredPolicyAcquisitionCostsAmortizationExpensePremiumDeficiencyReserve	0	usd
CY2023Q1	us-gaap	Investments Investments	299461000	usd
CY2023Q1	clov	Available For Sale Securities And Held To Maturity Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAndHeldToMaturitySecuritiesAccumulatedGrossUnrealizedGainBeforeTax	155000	usd
CY2023Q1	clov	Available For Sale Securities And Held To Maturity Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAndHeldToMaturitySecuritiesAccumulatedGrossUnrealizedLossBeforeTax	7276000	usd
CY2023Q1	us-gaap	Receivables From Customers ReceivablesFromCustomers	56900000	usd
CY2023Q1	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	292340000	usd
CY2022Q4	us-gaap	Investments Investments	336997000	usd
CY2022Q4	clov	Available For Sale Securities And Held To Maturity Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAndHeldToMaturitySecuritiesAccumulatedGrossUnrealizedGainBeforeTax	48000	usd
CY2022Q4	clov	Available For Sale Securities And Held To Maturity Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAndHeldToMaturitySecuritiesAccumulatedGrossUnrealizedLossBeforeTax	9528000	usd
CY2022Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	327517000	usd
CY2023Q1	us-gaap	Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount	15000	usd
CY2023Q1	us-gaap	Held To Maturity Securities Debt Maturities Within One Year Fair Value HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue	15000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	159062000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	156542000	usd
CY2023Q1	us-gaap	Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount	631000	usd
CY2023Q1	us-gaap	Held To Maturity Securities Debt Maturities After One Through Five Years Fair Value HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	553000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	139643000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	135132000	usd
CY2023Q1	us-gaap	Held To Maturity Securities Debt Maturities After Five Through Ten Years Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount	0	usd
CY2023Q1	us-gaap	Held To Maturity Securities Debt Maturities After Five Through Ten Years Fair Value HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	0	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost	0	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	0	usd
CY2023Q1	us-gaap	Held To Maturity Securities Debt Maturities After Ten Years Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesAfterTenYearsNetCarryingAmount	110000	usd
CY2023Q1	us-gaap	Held To Maturity Securities Debt Maturities After Ten Years Fair Value HeldToMaturitySecuritiesDebtMaturitiesAfterTenYearsFairValue	98000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost	0	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	0	usd
CY2023Q1	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	756000	usd
CY2023Q1	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	666000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis	298705000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	291674000	usd
CY2023Q1	us-gaap	Net Investment Income NetInvestmentIncome	3935000	usd
CY2022Q1	us-gaap	Net Investment Income NetInvestmentIncome	310000	usd
CY2023Q1	clov	Debt Securities Available For Sale And Held To Maturity Continuous Unrealized Loss Position Year One Fair Value DebtSecuritiesAvailableForSaleAndHeldToMaturityContinuousUnrealizedLossPositionYearOneFairValue	84389000	usd
CY2023Q1	clov	Debt Securities Available For Sale And Held To Maturity Continuous Unrealized Loss Position Year One Accumulated Loss DebtSecuritiesAvailableForSaleAndHeldToMaturityContinuousUnrealizedLossPositionYearOneAccumulatedLoss	575000	usd
CY2023Q1	clov	Debt Securities Available For Sale And Held To Maturity Continuous Unrealized Loss Position12 Months Or Longer Fair Value DebtSecuritiesAvailableForSaleAndHeldToMaturityContinuousUnrealizedLossPosition12MonthsOrLongerFairValue	155066000	usd
CY2023Q1	clov	Debt Securities Available For Sale And Held To Maturity Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleAndHeldToMaturityContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	6701000	usd
CY2023Q1	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Fair Value DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionFairValue	239455000	usd
CY2023Q1	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionAccumulatedLoss	7276000	usd
CY2023Q1	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Number Of Positions Year One DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionNumberOfPositionsYearOne	79	position
CY2023Q1	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Number Of Positions12 Months Or Longer DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionNumberOfPositions12MonthsOrLonger	25	position
CY2023Q1	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionNumberOfPositions	104	position
CY2022Q4	clov	Debt Securities Available For Sale And Held To Maturity Continuous Unrealized Loss Position Year One Fair Value DebtSecuritiesAvailableForSaleAndHeldToMaturityContinuousUnrealizedLossPositionYearOneFairValue	142553000	usd
CY2022Q4	clov	Debt Securities Available For Sale And Held To Maturity Continuous Unrealized Loss Position Year One Accumulated Loss DebtSecuritiesAvailableForSaleAndHeldToMaturityContinuousUnrealizedLossPositionYearOneAccumulatedLoss	1380000	usd
CY2022Q4	clov	Debt Securities Available For Sale And Held To Maturity Continuous Unrealized Loss Position12 Months Or Longer Fair Value DebtSecuritiesAvailableForSaleAndHeldToMaturityContinuousUnrealizedLossPosition12MonthsOrLongerFairValue	147757000	usd
CY2022Q4	clov	Debt Securities Available For Sale And Held To Maturity Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleAndHeldToMaturityContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	8148000	usd
CY2022Q4	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Fair Value DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionFairValue	290310000	usd
CY2022Q4	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionAccumulatedLoss	9528000	usd
CY2022Q4	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Number Of Positions Year One DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionNumberOfPositionsYearOne	92	position
CY2022Q4	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Number Of Positions12 Months Or Longer DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionNumberOfPositions12MonthsOrLonger	24	position
CY2022Q4	clov	Debt Securities Available For Sale And Held To Maturity Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleAndHeldToMaturityUnrealizedLossPositionNumberOfPositions	116	position
CY2022Q4	us-gaap	Debt Securities Held To Maturity Allowance For Credit Loss DebtSecuritiesHeldToMaturityAllowanceForCreditLoss	0	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q1	us-gaap	Debt Securities Held To Maturity Allowance For Credit Loss DebtSecuritiesHeldToMaturityAllowanceForCreditLoss	0	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q1	clov	Proceeds From Sale Of Short Term Investments And Available For Sale Securities ProceedsFromSaleOfShortTermInvestmentsAndAvailableForSaleSecurities	15001000	usd
CY2022Q1	clov	Proceeds From Sale Of Short Term Investments And Available For Sale Securities ProceedsFromSaleOfShortTermInvestmentsAndAvailableForSaleSecurities	0	usd
CY2023Q1	clov	Proceeds From Maturity Of Short Term Investments And Debt Securities Available For Sale And Held To Maturity ProceedsFromMaturityOfShortTermInvestmentsAndDebtSecuritiesAvailableForSaleAndHeldToMaturity	63324000	usd
CY2022Q1	clov	Proceeds From Maturity Of Short Term Investments And Debt Securities Available For Sale And Held To Maturity ProceedsFromMaturityOfShortTermInvestmentsAndDebtSecuritiesAvailableForSaleAndHeldToMaturity	150000000	usd
CY2023Q1	clov	Short Term Investments And Available For Sale Securities Gross Realized Gains ShortTermInvestmentsAndAvailableForSaleSecuritiesGrossRealizedGains	0	usd
CY2022Q1	clov	Short Term Investments And Available For Sale Securities Gross Realized Gains ShortTermInvestmentsAndAvailableForSaleSecuritiesGrossRealizedGains	0	usd
CY2023Q1	clov	Short Term Investments And Available For Sale Securities Gross Realized Losses ShortTermInvestmentsAndAvailableForSaleSecuritiesGrossRealizedLosses	0	usd
CY2022Q1	clov	Short Term Investments And Available For Sale Securities Gross Realized Losses ShortTermInvestmentsAndAvailableForSaleSecuritiesGrossRealizedLosses	0	usd
CY2023Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	usd
CY2022Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	usd
CY2023Q1	us-gaap	Deposits Deposits	14400000	usd
CY2022Q4	us-gaap	Deposits Deposits	14300000	usd
CY2023Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	292574000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	327766000	usd
CY2023Q1	us-gaap	Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity within the liability for Unpaid claims, including claims adjustment expenses, for the three months ended March 31, 2023 and 2022, respectively, is summarized as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross and net balance, beginning of period</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,395 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #ffffff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,258 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,056)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total incurred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,062 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,095 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,360 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,034 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,581 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,941 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,214 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross and net balance, end of period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,516 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt double #ffffff;border-top:0.25pt solid #ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,018 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes amounts due to related parties. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Differs from the total Unpaid claims amount reported on the Consolidated Balance Sheets due to the fact the figure here excludes unpaid claims for the Company's Non-Insurance operations of $4.1 million and $13.2 million at March 31, 2023 and 2022, respectively.</span></div>
CY2022Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	137395000	usd
CY2021Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	136137000	usd
CY2023Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	272258000	usd
CY2022Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	272151000	usd
CY2023Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	804000	usd
CY2022Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-7056000	usd
CY2023Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	273062000	usd
CY2022Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	265095000	usd
CY2023Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	167360000	usd
CY2022Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	164034000	usd
CY2023Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	104581000	usd
CY2022Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	84180000	usd
CY2023Q1	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	271941000	usd
CY2022Q1	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	248214000	usd
CY2023Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	138516000	usd
CY2022Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	153018000	usd
CY2023Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	104600000	usd
CY2023Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	800000	usd
CY2022Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-7100000	usd
CY2023Q1	clov	Ratio Of Current Year Medical Claims Paid As A Percent Of Current Year Net Medical Claims RatioOfCurrentYearMedicalClaimsPaidAsAPercentOfCurrentYearNetMedicalClaims	0.615
CY2022Q1	clov	Ratio Of Current Year Medical Claims Paid As A Percent Of Current Year Net Medical Claims RatioOfCurrentYearMedicalClaimsPaidAsAPercentOfCurrentYearNetMedicalClaims	0.603
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	5006473	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	2072752	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1.000
CY2023Q1	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.040
CY2023Q1	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.040
CY2023Q1	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	500000	usd
CY2022Q1	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	300000	usd
CY2023Q1	us-gaap	Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage	1.000
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	38617000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	40640000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	507500000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P4Y
CY2023Q1	clov	Share Based Compensation Arrangement By Share Based Payment Award Expense More Than Stock Based Compensation Plans ShareBasedCompensationArrangementByShareBasedPaymentAwardExpenseMoreThanStockBasedCompensationPlans	0.40
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	507500000	usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	22138777	shares
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	100000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.88
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y11M15D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	39800000	usd
CY2022Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2023Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q4	us-gaap	Income Tax Examination Penalties Accrued IncomeTaxExaminationPenaltiesAccrued	0	usd
CY2023Q1	us-gaap	Income Tax Examination Penalties Accrued IncomeTaxExaminationPenaltiesAccrued	0	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-72606000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-75490000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-72606000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-75490000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	478805067	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	478805067	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	473028651	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	473028651	shares
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	113522643	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	91462527	shares
CY2023Q1	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	0	usd
CY2022	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	0	usd
CY2023Q1	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	2500000	usd
CY2022Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	500000	usd
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2023Q1	clov	Non Insurance Performance Year Receivable Current NonInsurancePerformanceYearReceivableCurrent	552620000	usd
CY2022Q4	clov	Non Insurance Performance Year Receivable Current NonInsurancePerformanceYearReceivableCurrent	0	usd
CY2023Q1	clov	Non Insurance Performance Year Obligation Current NonInsurancePerformanceYearObligationCurrent	613057000	usd
CY2022Q4	clov	Non Insurance Performance Year Obligation Current NonInsurancePerformanceYearObligationCurrent	73844000	usd
CY2023Q1	clov	Non Insurance Performance Year Receivable Amortization NonInsurancePerformanceYearReceivableAmortization	184207000	usd
CY2022Q1	clov	Non Insurance Performance Year Receivable Amortization NonInsurancePerformanceYearReceivableAmortization	586715000	usd
CY2023Q1	clov	Non Insurance Performance Year Obligation Amortization NonInsurancePerformanceYearObligationAmortization	184207000	usd
CY2022Q1	clov	Non Insurance Performance Year Obligation Amortization NonInsurancePerformanceYearObligationAmortization	586715000	usd
CY2023Q1	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	205783000	usd
CY2022Q1	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	594898000	usd
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2023Q1	us-gaap	Ceded Premiums Earned CededPremiumsEarned	122000	usd
CY2023Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	317086000	usd
CY2023Q1	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	205783000	usd
CY2023Q1	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	4906000	usd
CY2023Q1	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	472490000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	55285000	usd
CY2023Q1	us-gaap	Assets Assets	1453589000	usd
CY2022Q1	us-gaap	Ceded Premiums Earned CededPremiumsEarned	119000	usd
CY2022Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	278169000	usd
CY2022Q1	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	594898000	usd
CY2022Q1	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	1312000	usd
CY2022Q1	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	861722000	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	12657000	usd
CY2022Q1	us-gaap	Assets Assets	2679894000	usd
CY2023Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	55285000	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	12657000	usd
CY2023Q1	us-gaap	Labor And Related Expense LaborAndRelatedExpense	70207000	usd
CY2022Q1	us-gaap	Labor And Related Expense LaborAndRelatedExpense	69091000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	59215000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	57697000	usd
CY2023Q1	clov	Premium Deficiency Testing Benefit Long Duration Contract Amount PremiumDeficiencyTestingBenefitLongDurationContractAmount	-1810000	usd
CY2022Q1	clov	Premium Deficiency Testing Benefit Long Duration Contract Amount PremiumDeficiencyTestingBenefitLongDurationContractAmount	-27476000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	279000	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	826000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	0	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	403000	usd
CY2022Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	12394000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-72606000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-75490000	usd
CY2023Q1	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	2500000	usd
CY2022Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	500000	usd

Files In Submission

Name	View Source	Status
0001801170-23-000038-index-headers.html	Edgar Link	pending
0001801170-23-000038-index.html	Edgar Link	pending
0001801170-23-000038.txt	Edgar Link	pending
0001801170-23-000038-xbrl.zip	Edgar Link	pending
a3312023-exx102.htm	Edgar Link	pending
a3312023-exx181.htm	Edgar Link	pending
a3312023-exx311.htm	Edgar Link	pending
a3312023-exx312.htm	Edgar Link	pending
a3312023-exx321.htm	Edgar Link	pending
a3312023-exx322.htm	Edgar Link	pending
clov-20230331.htm	Edgar Link	pending
clov-20230331.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
clov-20230331_cal.xml	Edgar Link	unprocessable
clov-20230331_def.xml	Edgar Link	unprocessable
clov-20230331_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
clov-20230331_pre.xml	Edgar Link	unprocessable
clov-20230331_htm.xml	Edgar Link	completed
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CLOV
CLOVER HEALTH INVESTMENTS, CORP. /DE Stock $clov

2023 Q1 Form 10-Q Financial Statement

#000180117023000038 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLOV CLOVER HEALTH INVESTMENTS, CORP. /DE Stock $clov

2023 Q1 Form 10-Q Financial Statement

#000180117023000038 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLOV
CLOVER HEALTH INVESTMENTS, CORP. /DE Stock $clov